CD19 and immunoglobulin G4-related sclerosing disease: Recent advancements have highlighted flow cytometry of plasmablasts (CD19+CD20−CD27+CD38+) as a sensitive diagnostic tool for untreated IgG4-RD, with a sensitivity of 95% and specificity of 82% [16].